Roche makes hostile bid for Illumina

Wednesday 25 January 2012

The Roche group has stepped up its commitment to personalised medicine with the announcement of a hostile $5.7 billion bid for Illumina Inc of the US, a leading provider of molecular diagnostics. The all-cash offer values each share at $44.50.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland